{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.9","upperLimit":"56.4","value":"50.7"},{"groupId":"OG001","lowerLimit":"44.1","upperLimit":"55.6","value":"49.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"306"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"A MaHR was defined as a participant having either CHR or NEL. CHR was defined as: WBC ≤ ULN; ANC ≥ 1,000/mm\\^3; - platelets ≥ 100,000/mm\\^3; - no blasts or promyelocytes in PB; BM blasts ≤ 5%; \\< 5% myelocytes plus metamyelocytes in PB; basophils in PB \\< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (both lower limits had to be satisfied): platelets ≥ 20,000/mm\\^3 and \\< 100,000/mm\\^3; ANC \\> 500/mm\\^3 and \\<1,000/mm\\^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule. Percent: number of participants with MaHR /number of participants randomized.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant..","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"Participants were analyzed based on the treatment they were randomized to receive.","reportingStatus":"POSTED","timeFrame":"Randomization up to 2 years","title":"Percent of Participants With Major Hematological Response (MaHR) With 2 Years of Follow-up From Date of Last Enrollment - Randomized Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}